Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.

Metreleptin beneficial to patients with partial lipodystrophy

12 Jul 2019

Use of metreleptin for the treatment of patients with partial lipodystrophy (PL) is relatively safe and produces improvements in glycaemic control, hypertriglyceridaemia and liver volume, according to the results of an open-label study and its long-term extension phase.

The current analysis included 41 PL patients (median age, 34 years; 97.6 percent female) circulating leptin <12.0 ng/mL, and diabetes mellitus, insulin resistance or hypertriglyceridaemia who received metreleptin doses (once or twice daily) titrated to a mean of 0.124 mg/kg/day.

Treatment yielded significant reductions from baseline to month 12 in the following endpoints of interest: glycated haemoglobin (HbA1c; –0.6 percent) and fasting serum triglycerides (TGs; –20.8 percent), fasting plasma glucose (FPG; –1.2 mmol/L) and liver volume (–13.4 percent; p<0.05 for all).

The observed benefits extended to the subgroup of patients with baseline HbA1c ≥6.5 percent or TGs ≥5.65 mmol/L: HbA1c (−0.9 percent), fasting TGs (−37.4 percent), FPG (−1.9 mmol/L) and liver volume (−12.4 percent; p<0.05 for all). In this subgroup, 67.9 percent of patients achieved a ≥1-percent decrease in HbA1c or ≥30-percent decrease in fasting TGs, while 42.9 percent of patients achieved ≥2-percent or ≥40-percent reduction, respectively.

Long-term treatment with metreleptin in the said subgroup likewise resulted in substantial improvements in HbA1c, fasting TGs and FPG at months 12, 24 and 36 (p<0.05).

In terms of safety, the drug was well tolerated with no new safety signals. Commonly reported treatment-emergent adverse events were abdominal pain, hypoglycaemia and nausea.

The present data demonstrate the usefulness of metreleptin in the treatment of PL, especially for patients with more severe metabolic disease, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.